Navigation Links
Signalife and Heart One Global Research Agree to Merge
Date:7/7/2008

pany shall be owned by a minimum of 94% of the current actual common shareholders of Signalife, Inc. The merger agreement has an earn out provision where Heart One Global Research shareholders may receive an additional 9% of common stock under an earn out structure requiring the development of approximately $9.5 million of revenue in the short and short-mid term. Additionally, for all real and actual shareholders of Signalife, their delivery of shares to the tabulation firm will also entitle them to a preferred share with increased voting and equity rights. Details of this shall be disclosed as they become available and as the transaction progresses.

Rowland Perkins, Chief Executive Officer of Signalife, Inc., commented: "This merger is one that involves a company, and a business approach, that the Signalife Board has been looking at for some time. We are lucky to acquire this asset on these terms, and the team at Heart One Global Research will be a welcome addition -- both financially and intellectually -- to the Company. This opportunity allows Signalife to merge its "gold standard" ECG technologies with a cutting edge data storage, recall and management system that will allow doctors, practitioners and patients complete medical history based around their heart history that is the core of everyone's health picture. To do this on a worldwide basis with the assets Heart One brought to the table was something that we simply could not pass up."

Dr Stan Shepherd, Chief Executive Officer of Heart One Global Research, commented: "We know that the electronic medical record is at the heart of delivering both the most clinically-effective care and the most cost-effective care, the two key objectives of every healthcare system in the world. Putting Signalife's double award winning technology literally at the heart of our electronic health record, will give the merged company unique capabilities to transform the treatment and outcomes of one of the major causes
'/>"/>

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. HTG-Ventrex, Signalifes Contract Manufacturer, Acquired by Parker Hannifin Corporation
2. Signalife & Athletes Foundation Complete Second Mobile Health Screening
3. Signalife Establishes Signalcare Division
4. Signalife to Deploy Fidelity 100 Heart Monitors for AFL
5. Geisinger study: PTSD causes early death from heart disease
6. Get Healthy: Your Middle-Aged Heart Will Thank You
7. Gender differences and heart disease
8. WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market
9. American Heart Association Announces Fourth New Journal - Circulation: Cardiovascular Interventions to Debut in August
10. American Lung Association Report Finds Lung Disease Death Rates Increasing While Cancer, Heart Disease and Stroke Death Rates Are Decreasing
11. Certain anti-cancer agents could be harmful to patients with heart disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... global pharmaceutical giant Novartis bagged the contract to make ... vaccines. The $54.8 million contract// was finalised on Wednesday. ... million in federal contracts to fight a possible bird-flu ... also awarded contracts on Wednesday by the U.S. Department ...
... participate in a five-year study, to evaluate the risks of ... . ,Professor Lawrie Challis, an authority on mobile ... the Department of Health and the mobile phone industry. If ... of the study, which is expected to cost ?3 million. ...
... corporate downsizing not only affects those who lose jobs ... ,'Employees who remained in work after downsizing may ... said lead author Mika Kivimaki, from the Department of ... ,'In other words, enforced redundancies may boost mental ...
... failure, says a new study. // ,Gregg Fonarow ... of over 100,000 patients hospitalised because their heart condition was ... ,They found that the fatter the person, the less likely ... researchers reported their findings in the latest issue of the ...
... world were infected by HIV in each day of the year ... total, around 410,000 to 660,000 children under the age of 15 ... ,The report added that most of the children were infected ... half of the children infected last year would die of AIDS-related ...
... are becoming an increasingly important method for detecting malaria. ... a range of other strategies for controlling the disease ... insecticide-treated bed nets, indoor spraying against malaria-carrying mosquitoes and ... ,The tests are ideal for rural areas ...
Cached Medicine News:Health News:Downsizing Affects All Workers 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company ... on the early diagnosis and preventive treatment of cardiometabolic ... selected by Windhover as one of the "Top Biopharma ... This announcement is part of the conference event organized ...
... Pasteur, the vaccines division of the sanofi-aventis Group ... announced today the results of the Phase III ... Virus Vaccine) candidate compared to Fluzone (Influenza Virus ...  Data from the clinical trial assessing the immunogenicity ...
Cached Medicine Technology:GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 2Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 3Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 4Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 5
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
... Volk's super ... biomicroscopy lenses. Examination ... Provide unprecedented fundus ... addressing maximum potential ...
... series slit lamp biomicroscopy ... of the posterior pole. ... capability, specifically addressing maximum ... fundus image resolution & ...
Volk indirect lenses. High magnification views of the posterior pole....
Medicine Products: